TRPV4 mutations causing mixed neuropathy and skeletal phenotypes result in severe gain of function.

These findings demonstrate that the degree of baseline calcium elevation correlates with development of mixed phenotypes and sensitivity to pharmacologic channel inhibition, observations that will be critical for the design of future clinical trials for TRPV4 channelopathies.